Lenvatinib + Pembrolizumab + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Head and Neck Squamous Cell Carcinoma
Conditions
Head and Neck Squamous Cell Carcinoma
Trial Timeline
Oct 30, 2020 → Mar 28, 2025
NCT ID
NCT05523323About Lenvatinib + Pembrolizumab + Placebo
Lenvatinib + Pembrolizumab + Placebo is a phase 3 stage product being developed by Eisai for Head and Neck Squamous Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT05523323. Target conditions include Head and Neck Squamous Cell Carcinoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05523323 | Phase 3 | Completed |
| NCT04199104 | Phase 3 | Completed |
Competing Products
20 competing products in Head and Neck Squamous Cell Carcinoma